<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465527</url>
  </required_header>
  <id_info>
    <org_study_id>Prephase</org_study_id>
    <nct_id>NCT03465527</nct_id>
  </id_info>
  <brief_title>Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL</brief_title>
  <official_title>A Phase 2 Trial of Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kosin University Gospel Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 trial of pre-phase treatment before R-CHOP chemotherapy in elderly patients with
      newly diagnosed DLBCL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      R-CHOP Chemotherapy Cataract treatment with anterior steroids Phenotypic effects Evaluate the
      felony associated with the procedure for the primary purpose. This study evaluated efficacy,
      treatment outcome and safety for all patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(treatment-related mortality rate; TRM)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>treatment-related mortality rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IMWG fragility score before and after pre-phase treatment</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>International Myeloma Working Group,( IMWG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM and RR according to IMWG fragility score</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>International Myeloma Working Group,( IMWG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate; RR</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutropenic fever</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Incidence of neutropenic fever</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
Hydration, antibiotics, allopurinol, nutritional supplements, and so on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PrednisoLONE 50 MG</intervention_name>
    <description>Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically the first large-scaled B-cell lymphoma patient

          2. Diagnosis time 65 years old or older

          3. Patients planning R-CHOP chemotherapy

          4. Ann Arbor stage 2 (bulky ≥ diameter of 7cm), stage 3 or stage 4

          5. The International Prognostic Index (IPI) is a high intermediate or high risk

          6. Patients without prior history of lymphoma

          7. The decision to participate voluntarily in this study and the written consent of the
             patient

        Exclusion Criteria:

          1. Histologic subtypes other than CD20 positive broad-band macro-B cell lymphoma

          2. Large B-cell lymphoma involving the central nervous system

          3. Inadequate systemic disease A. Patients with clinically significant heart disease
             (congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia) or
             myocardial infarction within the past 6 months B. Serious neurological and psychiatric
             illness C. Serious active infection D. Other medical illnesses other than clinical
             trials

          4. If the drug used in this study is allergic

          5. If you do not agree to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <state>Sue-gu</state>
        <zip>60542</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kosin University Gospel Hospital</investigator_affiliation>
    <investigator_full_name>Ho Sup Lee</investigator_full_name>
    <investigator_title>MD, PhD. associate professor, Division of hematology-Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

